Serum Decorin, Interleukin-1β, and Transforming Growth Factor-β Predict Hypertrophic Scarring Postburn.
Hypertrophic scar after burn injury is a significant problem. Previous studies have examined the roles for decorin, interleukin-1β, and transforming growth factor-β1 in hypertrophic scar formation locally, but few have considered their systemic influence. The authors conducted a pilot study to examine whether serum levels of these molecules could predict hypertrophic scar formation. Serum levels were measured using enzyme-linked immunosorbent assay, and hypertrophic scar formation determined from chart reviews. Peripheral blood mononuclear cells and fibroblasts were stimulated with decorin, interleukin-1β, and transforming growth factor-β1, and expression of profibrotic molecules examined using flow cytometry, immunofluorescence microscopy, quantitative polymerase chain reaction, and mass spectrometry. Multiple linear regression analysis suggested early serum levels of decorin and interleukin-1β, and late serum levels of transforming growth factor-β1 were predictive of hypertrophic scar formation. Decorin up-regulated the expression of toll-like receptor 4 and C-X-C receptor 4 in peripheral blood mononuclear cells, and interleukin-1β up-regulated fibroblast production of C-X-C ligand 12. Transforming growth factor-β1 up-regulated, and interleukin-1β down-regulated, the production of profibrotic cytokines, collagen, and myofibroblast differentiation. The model predicting hypertrophic scar formation is supported by clinical results and limited in vitro experiments.
From the *Division of Plastic Surgery, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; †Wound Healing Research Group, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and ‡Critical Care, Department of Surgery, University of Alberta Hospital, Edmonton, Canada.
Peter O
PO
Kwan
Jie
J
Ding
Edward E
EE
Tredget
D000328:Adult; D002056:Burns / Q000097:blood / Q000473:pathology*; D002478:Cells, Cultured; D054377:Chemokine CXCL12 / Q000378:metabolism; D017439:Cicatrix, Hypertrophic / Q000097:blood / Q000175:diagnosis*; D058575:Decorin / Q000097:blood*; D005260:Female; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D019718:Receptors, CXCR4 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000097:blood*; D055815:Young Adult
C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D058575:Decorin; C508585:IL1B protein, human; D053583:Interleukin-1beta; D019718:Receptors, CXCR4; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D016212:Transforming Growth Factor beta